share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 8 09:05
Summary by Moomoo AI
SciSparc Ltd., a clinical-stage pharmaceutical company, has announced a series of significant intellectual property achievements in March 2024. On March 6, the company received a Canadian patent for its pain management technology aimed at reducing opioid use. This technology is particularly relevant given the global opioid epidemic and the potential to lower the addictive properties of opiates. The global opioid market is expected to grow, and SciSparc's patented technology could contribute to safer pain management solutions. Following this, on March 7, SciSparc was granted a patent in multiple European jurisdictions for its core technology involving cannabinoid combinations. This patent, which has been validated in several European countries, is part of SciSparc's strategy to enhance the safety and therapeutic benefits of...Show More
SciSparc Ltd., a clinical-stage pharmaceutical company, has announced a series of significant intellectual property achievements in March 2024. On March 6, the company received a Canadian patent for its pain management technology aimed at reducing opioid use. This technology is particularly relevant given the global opioid epidemic and the potential to lower the addictive properties of opiates. The global opioid market is expected to grow, and SciSparc's patented technology could contribute to safer pain management solutions. Following this, on March 7, SciSparc was granted a patent in multiple European jurisdictions for its core technology involving cannabinoid combinations. This patent, which has been validated in several European countries, is part of SciSparc's strategy to enhance the safety and therapeutic benefits of cannabinoids at low dosages. The company's portfolio includes drug development programs for various central nervous system disorders and rare diseases, utilizing THC and non-psychoactive CBD. Additionally, on March 8, SciSparc announced the enrollment of the first patient in a clinical trial for children with Autism Spectrum Disorder (ASD), marking progress in its SCI-210 development program. These developments are incorporated by reference into the company's registration statements filed with the SEC, indicating their significance for the company's future operations and regulatory compliance.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more